Split History
ETFs Holding ALRN »    ALRN Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Aileron Therapeutics is a clinical stage chemoprotection oncology company. ALRN-6924, Co.'s MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is a chemoprotective agent in clinical development to employ a biomarker strategy, in which Co. focuses on treating patients with p53-mutated cancers. Co.'s clinical development program for ALRN-6924 as a selective chemoprotective agent includes: Its completed Phase 1b open-label clinical trial evaluating ALRN-6924 as a chemoprotective agent in patients with p53-mutated small cell lung cancer, undergoing treatment with second-line topotecan. According to our ALRN split history records, Aileron Therapeutics has had 1 split.
ALRN split history picture
Aileron Therapeutics (ALRN) has 1 split in our ALRN split history database. The split for ALRN took place on November 11, 2022. This was a 1 for 20 reverse split, meaning for each 20 shares of ALRN owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 50 share position following the split.

When a company such as Aileron Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the ALRN split history from start to finish, an original position size of 1000 shares would have turned into 50 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Aileron Therapeutics shares, starting with a $10,000 purchase of ALRN, presented on a split-history-adjusted basis factoring in the complete ALRN split history. ALRN split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 06/29/2017
End date: 01/30/2023
Start price/share: $216.00
End price/share: $2.75
Dividends collected/share: $0.00
Total return: -98.73%
Average Annual Total Return: -54.18%
Starting investment: $10,000.00
Ending investment: $127.26
Years: 5.59
Date Ratio
11/11/20221 for 20
ALRN is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

ALT Split History
ALVR Split History
ALXA Split History
ALXN Split History
AMDA Split History
AMED Split History
AMGN Split History
AMN Split History
AMPE Split History
AMRI Split History

Also explore: ALRN shares outstanding history

Email EnvelopeFree ALRN Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Liminal BioSciences Inc. (LMNL)
Galway Metals Inc. (GWM.CA)
Lannett Company, Inc. (LCI)
Reed's, Inc. (REED)
Phio Pharmaceuticals Corp. (PHIO)
Swvl Holdings Corp (SWVL)
Sientra, Inc. (SIEN)
Eargo, Inc. (EAR)
Alterity Therapeutics Limited (ATHE)
Aytu BioPharma, Inc. (AYTU)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

ALRN Insider Buying

ALRN Split History | www.SplitHistory.com | Copyright © 2013 - 2023, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.